A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease

NCT02580617 | Unknown Phase 1

• 1 other identifier: ALLO-ASC-CD-101
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn' disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.

Conditions

Crohn's Disease

Outcome Measures

Primary Outcomes (1)

• Safety (Clinically measured abnormality of laboratory tests and adverse events)

  Clinically measured abnormality of laboratory tests and adverse events

  up to 4 weeks

Secondary Outcomes (2)

• CDAI value

  up to 4 weeks

• The ratio of patients applicable to CDAI <150

  Week 4

Study Arms (1)

ALLO-ASC

EXPERIMENTAL

Group 1: 5.0 x 10\^7 cells Group 2: 7.5 x 10\^7 cells Group 3: 10.0 x 10\^7 cells

Biological: ALLO-ASC

Interventions

ALLO-ASC BIOLOGICAL

Infusion for Crohn's disease

Also known as: ALLO-ASC-CD

ALLO-ASC

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is 18 to 65 years of age
• Subject who is diagnosed Crohn's disease by endoscopic or radiologic result during more than 6 months
• Subject who show intolerance or failure of conventional therapy (steroids, immunosuppressive and TNF-alpha inhibitor)
• Subject who is included CDAI 220-450 during screening period
• CRP\>0.5mg/dL during screening period
• Subject who show affected sites by crohn's disease in either ileum and large intestine or both of them, including more than 1 nonanastomotic ulcers as a result of colonoscopy.
• Subjects who satisfy those clinical examination value below during screening period.
• A. Hemoglobin ≥ 8.0g/dL B. WBC ≥ 3,000/μL C. Lymphocyte ≥ 500/μL D.100,000/μL ≤ Platelet ≤ 1,200,000/μL E. AST and ALT ≤ 3 x the upper limit of normal F. ALP ≤ 3 x the upper limit of normal G.Serum creatinine ≤ the upper limit of normal H.Serum albumin ≥ 2.0g/dL I.PT , aPTT≤ the upper limit of normal
• Negative for urine beta-HCG for women of childbearing age.
• Subject is able to give written informed consent prior to study start and to comply with the study requirements.

You may not qualify if:

• Subject with gastro-intestinal tract A. Crohn's disease which is invaded only proximal ileum. B. The evidence of an intra abdominal abscess during screening period. C. The evidence of an abscess around the anus during screening period. D. Conditions of subtotal colectomy or total colectomy. E. Short bowel syndrome. F. Subject who conduct elemental diet, tube feeding or parenteral nutrition within 3 weeks before enrollment.
• G. Subject who have ileostomy or colostomy. H Subject who have a bowel stricture of large intestine that may be significant by PI's decision during screening period.
• I. In case that the PI anticipates that patients need to get a surgical intestinal tract surgery caused by crohn's disease.
• J. Subject who have adenoma of large intestine K. Subject who have chronic inflammation-associated dysplasia.
• Subjects who have been received biological therapy within 60 days of enrollment..
• Subject with infectious disease A. Acute or chronic active HBV, HAV and HIV B. Active tuberculosis. C. IGRA (Interferon-Gamma Release Assay) positive D. All kinds of live vaccine inoculation except influenza vaccine within 4weeks before registration E. Pneumonia, pyelonephritis and Infection of Clostridium within 4weeks during screening visit.
• F.Subject has history of bacteremia or other serious bacterial or fungal infection in past 3 months.
• Subject who has malignant tumor or which is not cured yet
• Subject has any serious disease, in the opinion of the Investigator, would interfere with the evaluation of the study.
• Subject who has history of blood clots and other pathological arterial thrombosis or venous thrombosis
• Subject who has a hypersensitive reaction to bovine-derived proteins
• Subject who is surgery or trauma within 6 weeks before registration
• Subject who is pregnant or breast-feeding.
• Subjects who are unwilling to use an "effective" method of contraception during the study
• Subject who is experienced stem cell therapy

Sponsors & Collaborators

• Anterogen Co., Ltd.: lead

Study Sites (1)

Yonsei University College of Medicine

Seoul, South Korea

RECRUITING

MeSH Terms

Conditions

Crohn Disease

Condition Hierarchy (Ancestors)

Inflammatory Bowel Diseases; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases

Study Officials

• Won Ho Kim

  Yonsei University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Won Ho Kim, MD., PhD

CONTACT

82-2-2228-1951; kimwonho@yuhs.ac

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 15, 2015
• First Posted: October 20, 2015
• Study Start: November 9, 2015
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: August 25, 2023

Record last verified: 2023-08

Locations

KR (1)